Skip to main content
. 2022 Nov 16;27(4):228–237. doi: 10.1111/jns.12519

FIGURE 1.

FIGURE 1

Approaches to Transthyretin‐mediated Amyloidosis Treatment. The following are treatment modalities to replace, reduce, stabilize, or disrupt transthyretin (TTR) in the treatment of transthyretin‐mediated amyloidosis (ATTR). Replace TTR: liver transplant. Reduce TTR: ASO (inotersen, eplontersen); siRNA (patisiran, vutrisiran); Gene editing (NTLA‐2001). Stabilize TTR: tafamidis, acoramidis, diflunisal [off‐label use]. Disrupt amyloid fibrils: Combination therapy (doxycycline and tauroursodeoxycholic acid); Monoclonal antibodies (PRX004, NI006); Pan‐amyloid technologies (AT‐02, AT‐03, AT‐04 [all preclinical]).